AGP Executive Report
Last update: 3 hours agoBiotech Deal: GSK is buying Boston-based Nuvalent for $10.6 billion, adding three late-stage lung cancer drugs (including ROS1 and ALK inhibitors) as regulators review potential 2026 approvals. Clinical Pipeline: PureTech’s Seaport Therapeutics says repeat-dose Phase 1 data for GlyphAgo™ supports moving into Phase 2 trials for generalized anxiety disorder and sleep disturbance. Obesity/Metabolic Health: Boehringer Ingelheim’s survodutide drew attention at ADA 2026 with Phase 3 results showing large visceral and liver fat reductions alongside weight loss. Massachusetts Innovation: The Massachusetts Innovation Network named 2026 Eddies finalists, spanning biotech and climate startups. Regulatory/Access: A federal judge in Massachusetts struck down Trump’s $100,000 H-1B fee as an unlawful tax, a win that could ease hiring costs for healthcare and education employers. Public Health & Safety: Boston police are investigating the death of a child after a cardiac event in the South End. Local Care: Old Colony Elder Services honored volunteers supporting in-home and community services for older adults across Southeastern Massachusetts.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
